In the early trading session on April 2, brain-computer interface (BCI) concept stocks showed strong performance. BrainMove Aurora-B (06681.HK) opened higher and continued to rise, reaching an intraday high of over 10% to around HK$4.63, with trading volume significantly expanding and market attention rapidly increasing.

(Image Source: uSMART HK app)
On the news front, the company recently announced a strategic partnership with the Beijing Frontier Brain-Computer Interface Research Institute, with its subsidiary having completed the relevant agreements. The market views this collaboration as an important step for the company to enter the core BCI ecosystem.From an industry chain perspective, BCIs cover upstream hardware, midstream algorithms and system integration, and downstream medical and consumer applications. The sector has clear technological barriers and long-term growth potential. By partnering with research institutions, the company is expected to gain synergistic advantages in technology R&D, clinical translation, and real-world applications.
Industry observers generally believe that such collaborations not only help enhance a company's technological reserves but may also provide an early advantage in accessing future policies and project resources.
In recent years, BCIs have been included as a key national frontier technology, with top-level planning continuously strengthened. As the “15th Five-Year Plan” and related policies are implemented, the industry’s development logic is shifting from “technology exploration” to “application deployment.”Particularly in the medical field, BCIs are expected to improve treatment pathways for neurological diseases. With a large population of patients with neurological disorders in China, the potential demand provides a broad space for the industry.
Under the dual drive of policy and demand, the sector is likely to enter a critical stage from research to industrialization, and companies with technological accumulation and cooperative resources are more likely to stand out.
Overall, the rise in BrainMove Aurora-B is fundamentally the result of the convergence of “policy + technology + cooperation.” However, the BCI industry is still in its early stages, and commercialization from the laboratory will take time. In the future, whether the company can leverage this cooperation to achieve technological breakthroughs and commercial conversion will be a key factor in determining whether its valuation can continue to rise.
After logging into the uSMART HK app, click the “Search” button in the top-right corner of the page, enter the ticker code(06681.HK), and navigate to the details page to view transaction details and historical trends. Click the “Trade” button in the bottom-right corner, select the trade type, and submit your order after filling in the transaction conditions.

(Image Source: uSMART HK app)
